BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $42.60 Average PT from Analysts
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one […]
